3D Cell Culture Market, By Technology (Extracellular Matrices or Scaffolds, Bioreactors, Gels, Scaffold-free Platforms, Microchips), By Application (Research, Drug Discovery, Tissue Engineering, Clinical Applications, Stem Cell Biology), By End User (Research Labs & Institutes, Biopharmaceutical Industry, Hospitals And Diagnostic Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Nov 2023

Code : CMI534

Pages :172

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Global 3D Cell Culture Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global 3D cell culture market over the forecast period. The existence of advanced healthcare infrastructure, developed economies, the presence of important players, and different strategic efforts carried out by them jointly drive the industry. The regional market is also expected to be supported by a favorable regulatory environment, funding from government and private bodies for the development of three-dimensional culture models, and a sizable number of research institutions and universities looking into various stem-cell-based methods. Moreover, increasing business and facility expansion is also driving the market. For instance, on July 12, 2023, MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt Germany, announced the investment of US$ 25 million for the addition of 98,000 square feet of lab space and the ability to produce cell culture media at its facility in Lenexa, Kansas, U.S.

Global 3D Cell Culture Market - Cross Sectional Analysis:

3D cell culture in North America is on the rise due to several factors, including advancements in technology, increased adoption by researchers, growing applications in various fields, and growth initiatives by market players. For instance, in May 2021, CELLINK, a part of BICO, a bioconvergence startup, acquired Visikol Corp., a U.S.-based contract research services company offering leading services in 3D cell culture, 3D tissue imaging, multiplex imaging, and digital pathology to pharma and biotech companies. CELLINK has acquired all outstanding shares in Visikol Corp. for a purchase price of US$ 7.5 million on a cash- and debt-free basis.

Geographies covered:

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa